Literature DB >> 21557940

Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells.

Kazuya Sumi1, Kenji Tago, Tadashi Kasahara, Megumi Funakoshi-Tago.   

Abstract

JAK2 V617F mutant induces transformation through aberrant activation of various transcription factors. We found that the expression of Aurora kinase A (Aurka) was significantly induced by mutant JAK2 through c-Myc expression. Interestingly, mutant JAK2 enhanced resistance to cisplatin (CDDP)-induced DNA damage, and effectively suppressed apoptosis. Ectopic expression of Aurka in Ba/F3 cells exhibited similar resistance to CDDP, and this required kinase activity. Conversely, knockdown and inhibition of Aurka in cells expressing mutant JAK2 abolished the resistance to CDDP. Taken together, Aurka is most likely critical for resistance to DNA damage in cells transformed by JAK2 V617F mutant.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21557940     DOI: 10.1016/j.febslet.2011.04.068

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

1.  The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Authors:  Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

2.  Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.

Authors:  Ahmed Katsha; Mohammed Soutto; Vikas Sehdev; Dunfa Peng; M Kay Washington; M Blanca Piazuelo; Mohammed N Tantawy; H Charles Manning; Pengcheng Lu; Yu Shyr; Jeffrey Ecsedy; Abbes Belkhiri; Wael El-Rifai
Journal:  Gastroenterology       Date:  2013-08-29       Impact factor: 22.682

3.  AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers.

Authors:  Ahmed Katsha; Janet Arras; Mohammed Soutto; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Oncol       Date:  2014-06-03       Impact factor: 6.603

4.  The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.

Authors:  Vikas Sehdev; Ahmed Katsha; Jeffrey Ecsedy; Alexander Zaika; Abbes Belkhiri; Wael El-Rifai
Journal:  Cancer       Date:  2012-09-12       Impact factor: 6.860

Review 5.  Insights into the non-mitotic functions of Aurora kinase A: more than just cell division.

Authors:  Giulia Bertolin; Marc Tramier
Journal:  Cell Mol Life Sci       Date:  2019-09-27       Impact factor: 9.261

6.  Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

Authors:  Kevin R Kelly; Steffan T Nawrocki; Claudia M Espitia; Mengkun Zhang; Johnny J Yang; Swaminathan Padmanabhan; Jeffrey Ecsedy; Francis J Giles; Jennifer S Carew
Journal:  Int J Cancer       Date:  2012-06-28       Impact factor: 7.396

7.  Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2.

Authors:  Likun Li; Guang Yang; Chengzhen Ren; Ryuta Tanimoto; Takahiro Hirayama; Jianxiang Wang; David Hawke; Soo Mi Kim; Ju-Seog Lee; Alexei A Goltsov; Sanghee Park; Michael M Ittmann; Patricia Troncoso; Timothy C Thompson
Journal:  Mol Oncol       Date:  2012-12-31       Impact factor: 6.603

8.  AURKA suppression induces DU145 apoptosis and sensitizes DU145 to docetaxel treatment.

Authors:  Wei He; Min-Guang Zhang; Xiao-Jing Wang; Shan Zhong; Yuan Shao; Yu Zhu; Zhou-Jun Shen
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

9.  HDM2 regulation by AURKA promotes cell survival in gastric cancer.

Authors:  Vikas Sehdev; Ahmed Katsha; Janet Arras; Dunfa Peng; Mohammed Soutto; Jeffrey Ecsedy; Alexander Zaika; Abbes Belkhiri; Wael El-Rifai
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

10.  Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma.

Authors:  Mai Tsutsui; Hirofumi Kawakubo; Testsu Hayashida; Kazumasa Fukuda; Rieko Nakamura; Tsunehiro Takahashi; Norihito Wada; Yoshiro Saikawa; Tai Omori; Hiroya Takeuchi; Yuko Kitagawa
Journal:  Int J Oncol       Date:  2015-07-16       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.